ArticleScientific reports2020

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.

Kenji Tsuchihashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.